Cannabinoids, Pain, and Opioid Use Reduction: The Importance of Distilling and Disseminating Existing Data

被引:11
作者
Hutchison, Kent E. [1 ]
Hagerty, Sarah L. [1 ]
Galinkin, Jeffrey [2 ]
Bryan, Angela D. [1 ]
Bidwell, L. Cinnamon [3 ]
机构
[1] Univ Colorado, Dept Psychol & Neurosci, Muenzinger Bldg, Boulder, CO 80309 USA
[2] Univ Colorado, Sch Med, Pediat Anesthesiol, Aurora, CO USA
[3] Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA
关键词
cannabis; pain; opioids; CHRONIC NONCANCER PAIN; CROSS-SECTIONAL SURVEY; MEDICAL CANNABIS; OROMUCOSAL SPRAY; NEUROPATHIC PAIN; UNITED-STATES; BACK-PAIN; SATIVEX(R); ADULTS; DRUG;
D O I
10.1089/can.2018.0052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for pain and to reduce use of opioids, and cannabis-derived products demonstrate at least modest efficacy in the treatment of pain in randomized controlled trials. In addition, surveillance studies from countries that have approved the use of Sativex, which is a cannabis-based product, have demonstrated that a combination of Delta 9-tetrahydrocannabinol and cannabidiol has low potential for harm, is well tolerated, and is helpful to patients. Given the number of people in the United States who are already using cannabis to manage pain and opioid use in state-regulated markets, it is imperative to conduct additional research in these areas, and to disseminate information on how to minimize harm and maximize any benefits of using cannabinoids to mitigate pain and reduce opioid use. The purpose of this article is to call attention to the fact that cannabis is being used in the management of chronic pain. Thus, this article also provides a set of guidelines on how to approach using cannabis to treat pain.
引用
收藏
页码:158 / 164
页数:7
相关论文
共 75 条
[61]   Public opinion and medical cannabis policies: examining the role of underlying beliefs and national medical cannabis policies [J].
Sznitman, Sharon R. ;
Bretteville-Jensen, Anne Line .
HARM REDUCTION JOURNAL, 2015, 12
[62]   Role of Alternative Therapies for Chronic Pain Syndromes [J].
Thomas, Donna-Ann ;
Maslin, Benjamin ;
Legler, Aron ;
Springer, Erin ;
Asgerally, Abbas ;
Vadivelu, Nalini .
CURRENT PAIN AND HEADACHE REPORTS, 2016, 20 (05)
[63]   Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain [J].
Turk, DC .
CLINICAL JOURNAL OF PAIN, 2002, 18 (06) :355-365
[64]   Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products [J].
Vandrey, Ryan ;
Raber, Jeffrey C. ;
Raber, Mark E. ;
Douglass, Brad ;
Miller, Cameron ;
Bonn-Miller, Marcel O. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (24) :2491-2493
[65]   Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study [J].
Vigil, Jacob M. ;
Stith, Sarah S. ;
Adams, Ian M. ;
Reeve, Anthony P. .
PLOS ONE, 2017, 12 (11)
[66]  
Wade Derick, 2012, Expert Rev Neurother, V12, P9, DOI 10.1586/ern.12.12
[67]   Adverse effects of medical cannabinoids: a systematic review [J].
Wang, Tongtong ;
Collet, Jean-Paul ;
Shapiro, Stan ;
Ware, Mark A. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 178 (13) :1669-1678
[68]   Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy [J].
Ward, Sara Jane ;
McAllister, Sean D. ;
Kawamura, Rumi ;
Murase, Ryuchi ;
Neelakantan, Harshini ;
Walker, Ellen A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (03) :636-645
[69]   Smoked cannabis for chronic neuropathic pain: a randomized controlled trial [J].
Ware, Mark A. ;
Wang, Tongtong ;
Shapiro, Stan ;
Robinson, Ann ;
Ducruet, Thierry ;
Huynh, Thao ;
Gamsa, Ann ;
Bennett, Gary J. ;
Collet, Jean-Paul .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (14) :E694-E701
[70]   The "Toll" of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting Glia [J].
Watkins, Linda R. ;
Hutchinson, Mark R. ;
Rice, Kenner C. ;
Maier, Steven F. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (11) :581-591